Eurofins agrees to acquire SYNLAB’s clinical diagnostics operations in Spain
SYNLAB’s clinical diagnostics operations in Spain provide clinical diagnostics testing, including genetics and anatomical pathology services, throughout the country, achieving revenues of approximately €140m in 2023. The Eurofins network’s clinical diagnostics operations in Spain are led by Eurofins Megalab, a specialist in all types of clinical diagnostics testing and in managing intra-hospital laboratories in Spain.
Upon completion of the transaction, Eurofins will become a leading clinical diagnostics operator in Spain with a significant presence and capacity to provide services to public and private clients and cover all regions in the country. The combined company will have a highly specialised workforce of more than 2,000 employees and a best-in-class portfolio of clinical diagnostic laboratory tests, capable of providing high-quality services based on the latest technology and scientific medical advances. In addition, healthcare consumers in Spain will have access to an extensive network of laboratories and blood collection points with the capacity to serve more than 10 million patients and process 100 million laboratory tests annually.
Comment from Dr Gilles Martin, Eurofins CEO: “This acquisition confirms Eurofins’ commitment to providing the best clinical diagnostic testing services to the Spanish market. It is our aim to always be the most trusted and technologically advanced partner of choice for our clients, providing high quality and accessible testing services to both the private and public sector, including regional healthcare services, private hospital groups and insurance companies.”
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.